|Articles|June 22, 2017
PAREXEL is Acquired by Pamplona Capital Management
Advertisement
PAREXEL International Corporation announced that Pamplona Capital Management, LLP has acquired all of its outstanding shares, including Parexel's net debt, for $88.10 per share in cash-valued at approximately $5 billion.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
2
Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work
3
ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment
4
Breaking the Efficacy Ceiling in IBD and Beyond
5